Zhang and his colleagues recently discovered the binding pocket for these positive modulators of SK/IK channels. This pocket is located at the interface between the channel and calmodulin. Dr. Zhang and his colleagues performed screening of a large number of compounds in silico, to find those fitting into the binding pocket. I performed electrophysiological recordings to evaluate the efficacy and the potency of these modulators on SK2 channels. We discovered a correlation between the total binding energy values calculated from the structures and the potencies determined from electrophysiological recording. Chapter 3 9 Methodology 9 3.1 Virtual high throughput screening (vhts) for sk channel modulators. 
Ataxia
Ataxia, a Greek word that means 'loss of order,' is used medically to describe a devastating neurological disorder characterized by lack of muscle control during voluntary movements, difficulties with gait, problems with clarity of speech, and intention tremor, often as a result of cerebellar or spinocerebellar neurodegeneration (Carlson et al., 2009 ). The cause of such neurodegeneration can be from brain tumor, multiple sclerosis, alcoholism or a congenital genetic defect (Carlson et al., 2009; Matilla-Dueñas et al., 2010; Orr, 2012) . There are more than fifty different types of hereditary ataxias taking place during childhood or adulthood. Most of ataxias progress over a number of years, and the patients eventually lose the ability to swallow and breathe smoothly, which can be fatal. The most common type of ataxia is a cerebellar ataxia that is caused by a dysfunction of the cerebellum or in one of its pathways. Spinocerebellar ataxia (SCA) is an inherited form of ataxia in an autosomaldominant pattern. SCA is caused by irregular function of the spinocerebellum, the portion of the cerebellar cortex that receives somatosensory signals from the spinal cord (Orr, 2012; Orr and Zoghbi, 2007) . Currently, twenty-eight autosomal dominant SCAs have been described (Matilla-Dueñas et al., 2010) . The autosomal dominant SCAs are typically progressive, late-onset, and often lethal neurodegenerative illnesses.
Treatment of Ataxia
There is no cure that can specifically treat ataxia or the symptoms of ataxias.
However, understanding the disease can be helpful to treat, cure, or prevent it. The cerebellum coordinates motor movement and helps maintain balance and posture. It has three deep nuclei that provide the main output of the cerebellum. In neurodegenerative ataxias, neuronal death usually occurs as a result of prolonged period of neuronal dysfunction (Shakkottai et al., 2011) . The cerebellar Purkinje cells (PCs) are affected in many types of ataxias (Carlson et al., 2009; Orr, 2012; Shakkottai et al., 2004) . PCs are the only output source of cerebellar cortex, and they primarily promote inhibitory signals to the deep cerebellar nuclei (DCN). The dysfunction of pacemaking activity in PCs is one of the primary causes for the symptom of early stage ataxia (Kasumu et al., 2012b; Shakkottai et al., 2011) . As this malfunction of PCs would be expected to cause DCN hyperexcitability. The modulation of the DCN firing rate by PC input is believed to be responsible for coordination of movement.
Therefore, a direct relationship between increased DCN firing rate and ataxia can be concluded (Shakkottai et al., 2004) . Disruptions of regular cerebellar PCs activities have been identified in studies with mouse models of Episodic Ataxia EA2 (Walter et al., 2006) , Cerebellar Ataxia (Gao et al., 2012) , Spinocerebellar Ataxia SCA3 (Shakkottai et al., 2011) and SCA2 (Kasumu et al., 2012b) . However, cerebellar ataxia could be caused without disturbance of PCs output. One approach to increase the firing rate of the DCN is to selectively block the SK channels. Cerebellar ataxias were observed in a transgenic (Tg) mice that expressed a dominant negative isoform of SK channel (Shakkottai et al., 2004) . Hence, in cerebellar ataxias, the pharmacological activation of SK channel can serve neuroprotective roles (Hosy et al., 2011) . Here, using electrophysiology, the potency of two positive modulators on the SK2 channels was demonstrated.
REVIEW OF LITERATURE

Overview
Ion channels are the essential elements of the excitable cells that are responsible for the electrical signaling in nerves, muscles, and synapses. They are macromolecular pores that conduct and carry ions through the cell membrane. These channels open or close their pores to permit or block the ion flow in response to extracellular stimuli such as a membrane potential change (Wei and Lee, 2006) .
Small conductance Ca 2+-activated potassium SK channels
Ataxias are often disabling with no symptomatic therapy available.
Consequently, it seems appropriate to search for more effective approaches. The dysfunction of PCs leads to hyperexcitability of the Deep Cerebellar Nuclei (DCN), which results in cerebellar ataxia. The SK channels are a unique group of potassium ion channels that are activated by intracellular Ca2+ ions (Stocker, 2004; Kovalevskaya et al., 2013) . Potassium efflux through these channels modulates cell excitability. Thus, SK channels have been recognized as potential therapeutic drug targets for ataxia. SK channels have tetrameric architecture, and each channel subunit is consisted of six transmembrane α-helical domains (Zhang et al., 2013 regulates the firing frequency of action potentials for many types of neurons . SK channels emerged as one of the principle ion channels involved in the pacemaking of PCs. Among the three subtypes of SK channels, SK2 is the predominant subtype expressed in PCs (Cingolani et al., 2002; Sailer et al., 2004) .
SK Channels Positive modulators (PAM)
Over the past decade, a significant number of compounds have been developed targeting SK/IK channels. 1-EBIO (1-ethyl-2-benzimidazolinone), the first positive modulator was identified twenty years ago, potentiates SK/IK channel activity, and modulates neuronal excitability (Devor et al., 1996) . DCEBIO was developed from structural optimization of 1-EBIO, and it has about twenty-fold higher potency than 1-EBIO (Cui et al., 2014) . NeuroSearch A/S, a Scandinavian biopharmaceutical company has developed a relatively potent IK/SK channels positive modulator NS309
(3-oxime-6,7-dichloro-1H-indole-2,3-dione) (Strøbaek et al., 2004) . 1-EBIO and NS309 are non-selective positive modulators. These modulators cannot activate the SK/IK channels without the presence of Ca2+. Accordingly, they are termed as SK/IK channel positive modulators because they enhance the Ca2+ sensitivity of the SK/IK channels. Despite this progress, many modulators often suffer from low potency (Pedarzani and Stocker, 2008) . Limited knowledge about the binding site for the compounds reflected in delaying the development of more effective agents targeting SK channels.
The Binding Pocket
A binding pocket exists for SK channels positive modulators at the SK channel/CaM interface. Dr. Zhang and his colleagues discovered this binding site several years ago (Zhang et al., 2012) . Two FDA approved SK modulators (Chlorzoxazone and Riluzole) in addition to bound in Calmodulin DCEBIO also shared the same binding pocket in SK channels. Channel amino acid residues A477 and L480 interact with the modulators (fig.1A ). CHAPTER 3
METHODOLOGY
The identification of potent and selective SK modulators could alleviate the symptom of ataxia, in addition to providing pharmacological tools to probe the important roles of SK channels in the pacemaking of cerebellar PCs during the development of ataxia. The computer-based approach is able to screen a large number of compounds in silico, to find those fitting into the binding pocket. Electrophysiology expertise would be critical in characterizing the new modulators in detail.
Virtual High Throughput Screening (vHTS) for SK channel modulators.
The protein structure from SK2-a fragment complexed with NS309 (PDB: 
Electrophysiology:
SK2 channels were expressed in HEK293 cells. A calcium phosphate method was used for co-transfection of rat SK2 cDNA in pIRES2-AcGFP1 vector, together with rat CaM cDNA in pcDNA3.1(+) vector. Channel activities were recorded from GFP positive cells 1-2 days after transfection ( figure.3-A Currents were recorded using an inside-out patch configuration. The intracellular face was initially exposed to a zero-Ca 2+ bath solution, and subsequently to bath solutions with increasing 0.1 µM Ca 2+ . Currents were recorded by repetitive 1 sec-voltage ramps from -100 mV to +100 mV from a holding potential of 0mV. One minute after switch bath solutions, ten sweeps, with a one-second interval, were recorded at each compound concentration in the presence of 0.1 µM Ca 2+ . The integrity of the patch was examined by switching the bath solution back to the zeroCa 2+ buffer.
Data analysis:
To construct the dose-response curve, the current amplitudes were normalized at maximal concentration. The normalized currents were plotted as a function of the concentrations of each compound. Relative currents at -100 mV were plotted as a function of compound concentrations. Half-activation compound concentration (EC50) and Hill coefficients were determined by fitting the data points obtained from individual experiments to a standard dose-response curve (y = 100/(1 + (x/EC50)^-Hill)). (B) The intracellular side of the channel is exposed to drug in different concentrations applied to the bath.
RESULTS AND DISCUSSION
Activation of SK2 channels by Ca 2+
Dose dependent activation of SK2 channels by Ca 2+ was measured first. The raw current traces are indicated in fig. 5A . The threshold Ca 2+ concentration was determined to be 0.1 µM as shown in fig.5B . This threshold Ca 2+ concentration is a minimal concentration of Ca 2+ that is required for the modulators. As such, all following experiments were performed in the presence of 0.1 µ M Ca 2+ .
Potentiation of SK2 channels by Compounds #11 and #14
Before I started in the lab, Dr. Cui in Northeastern University has performed the vHTS, Dr. Zhang and other lab members has purchased and screened the top 100 hit compounds from the vHTS. Dr. Zhang and other lab members has identified compound #11 and compound #14 as two novel SK channel positive modulators.
After I started in the lab, in order to determine the dose dependent potentiation of SK2 channels by these compounds, SK2 channels were expressed in HEK293 cells, and their responses to compound #11 and compound #14 were recorded in the presence of 0.1 µM Ca 2+ in the bath solution.
Compound #11
SK2 channels showed very minimal activation upon application of a 0.1 µM Ca 2+ solution (Fig. 6B) . The channel activity was potentiated by compound #11 with increasing concentrations, from 0.3 µM up to 300 µM. The maximal response to 300 µM of compound 11 in the presence of 0.1 µM Ca 2+ is 94.60 ± 3.03% of the maximal current induced by µM Ca 2+ (Fig. 7) . Compound 11 dose dependently potentiate the SK2 channel activity (Fig. 7A) , with the EC50 of 3.87±0.88µM (Fig. 7B) and a Hill coefficient of 1.40±0.14 (n=8).
Compound #14
SK2 channels opened slightly upon application of a 0.1 µM Ca 2+ solution (Fig. 6C) .
The channel activity is further potentiated by compound #14 with increasing concentrations, from 3µM up to 600 µM. In the presence of 0.1 µM Ca 2+ , the maximal response to 600 µM of compound 14 is 92.03± 3.44% of the maximal current induced by µM Ca 2+ (Fig. 7) . Compound 14 dose dependently potentiate the SK2 channel activity (Fig. 7A) , with the EC50 of 33.24±4.80µM (Fig. 7B ) and a Hill coefficient of 1.40±0.15 (n=9). The correlation between the total interaction energy and the potency of these four compounds were shown in (Fig. 8 ). There is a strong correlation between these two involved in the pacemaking of PCs (Womack and Khodakhah, 2003) . SK2 is the predominant subtype expressed in PCs. SK channels modulate the afterhyperpolarization of the PCs that occurs after action potential generation.
Therefore, SK channel positive modulators can be effective in alleviating some behavioral and neuropathological symptoms of ataxia in animal models (Shakkottai et al., 2011; Walter et al., 2006; Shakkottai et al., 2004; Kasumu et al., 2012a) . Several small molecule modulators of SK channels have been identified previously. Riluzole, an SK channel modulator, yielded promising results in a phase II clinical trial of a mixed population of ataxic patients (Ristori et al., 2010) . Despite these promising results, the potency of both agents is not satisfactory for widespread clinical application.
The SK channel activator 1-EBIO has low potency, whereas NS309 is a potent SK channel modulator (Fig. 7A) . Compound #11 and compound #14 were identified as positive modulators of SK2 channels. The purpose of this study is to characterize the modulators #11 and #14 in details. To achieve this goal, an inside-out patch method was used to record the currents as the inside surface of the SK2 channel was exposed to different drug concentrations applied to the bath. depicts that compound #11 potently activated SK2 channels more than compound #14.
Moreover, The EC50 of compound is less than the EC50 of compound #14. The EC50
indicates how much of the agent is needed to achieve the half-maximal response. The potency of the compound is inversely related to the EC50. The more potent the agent the smaller the EC50 will be. Thus, compound # 11 can be considered as a highly potent SK channel modulator, but when compared to NS309, compound # 11 is less potent than the most potent modulator, NS309. Using electrophysiology, I evaluated the efficacy and potency of two positive modulators (compounds 11 and 14) on the SK2 channels. The efficacy values of these two compounds are not significantly different from the efficacy of 1-EBIO and NS309 as reported previously by Dr. Zhang ( Fig. 10) , whereas the potency values of 1-EBIO, compound 14, compound 11 and NS309 are significantly different from each other (Fig. 7B) . Utilizing the previous data from Dr. Zhang on the potency of two other modulators (1-EBIO and NS309) and the crystal structures of the binding pocket of the compounds determined by Dr. Nam, I found a correlation between the potency of these compounds and the interaction energy of the compounds to their binding pocket ( fig. 8 ). These structure-activity relationship studies will provide valuable information on how the potency of the compounds can be improved through chemical modification, which will facilitate drug discovery targeting SK channels to combat ataxia. The results described in this thesis have been published in the Scientific Report journal on December 7, 2017 (Nam et al., 2017) . compound 11(n=8), compound 14(n=9) and NS309(n=8).
